Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

European Research Council grant · Running

PICODROP-MS Exploring the Applications of Picodroplet Mass Spectrometry

Coordinator
University of Bristol, United Kingdom
Runs
1 January 2025 to 30 June 2026
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101188956

What the project is doing

In the project's own words, from its summary on CORDIS.

Mass spectrometry (MS) is a widely applied analytical tool underpinning important commercial sectors like biotechnology, pharmaceutics, and environmental analysis. A significant drawback is that the analysis is destructive, resulting in irretrievable sample loss and making MS nonideal when sample is expensive or scarce. We pioneered a technology capable of reducing the amount of sample consumed during MS by >4000 times compared to the existing state-of-the-art by using picolitre (10^-12 L) droplets.

Because these sample volumes are so small, our technology will significantly accelerate otherwise time-consuming preparative chemistry, benefitting end users in the above-mentioned sectors. Anticipated commercial benefits include improved cost-effectiveness and increased productivity gains arising from >99.9% cost savings on samples and substantial cost savings on staff time. The commercial adoption of our technology will lead to new services and increased sales by enabling analysis of samples too scarce for current technologies.

The considerable reduction in sample consumption will provide environmental benefits, and the capability to accelerate e.g. the drug discovery process may yield health benefits. Consequently, our picodroplet MS technology has the potential to become the method of choice for a diverse range of MS end users. To achieve these envisioned impacts, we will develop relationships with key industrial stakeholders in the analytical instrumentation sector and, building on our recent patent application, advance our IPR strategy by evaluating market and licensee requirements.

We will engage directly with leading MS end users to quantify the benefits of our technology in the important application areas of reaction discovery, biomolecular analysis, and environmental sampling. This PoC will facilitate comprehensive evaluation of our technology’s strengths relative to competitors and maximise its commercial potential.

Topics

Who is involved

OrganisationCityCountryRole
University of BristolBristolUnited KingdomCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI